Literature DB >> 19572041

An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

.   

Abstract

Entities:  

Year:  2009        PMID： 19572041      PMCID： PMC2697917     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  36 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 2.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

Authors: 
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

4.  Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record.

Authors:  Marinos C Dalakas; Wayne M Clark
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

5.  Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Authors:  J M Boyle; R H Buckley
Journal:  J Clin Immunol       Date:  2007-06-19       Impact factor: 8.317

6.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

7.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

8.  Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy.

Authors:  H W Eijkhout; P J van den Broek; J W M van der Meer
Journal:  Neth J Med       Date:  2003-06       Impact factor: 1.422

9.  Guidelines on the use of intravenous immune globulin for hematologic conditions.

Authors:  David Anderson; Kaiser Ali; Victor Blanchette; Melissa Brouwers; Stephen Couban; Paula Radmoor; Lothar Huebsch; Heather Hume; Anne McLeod; Ralph Meyer; Catherine Moltzan; Susan Nahirniak; Stephen Nantel; Graham Pineo; Gail Rock
Journal:  Transfus Med Rev       Date:  2007-04

10.  Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

Authors:  Paula Jane Busse; Samiya Razvi; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793
View more
  1 in total

1.  Comparative Study of Two ELISA Kits for Estimation of Antibodies to Hepatitis B Virus in Human Normal Immunoglobulin and Specific Immunoglobulin Intended for Intravenous or Intramuscular Use.

Authors:  J P Prasad; Y Madhu; Arushi Mandhan; Payal Garg; Anu Prakash; Varsha Singh; Daud Ali; Prdeep Kumar; Surinder Singh; G R Soni; Varun Singh
Journal:  Indian J Clin Biochem       Date:  2016-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.